Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Theravance Biopharma (TBPH) EBITDA Margin: 2013-2025

Historic EBITDA Margin for Theravance Biopharma (TBPH) over the last 13 years, with Sep 2025 value amounting to 18.29%.

  • Theravance Biopharma's EBITDA Margin rose 9315.00% to 18.29% in Q3 2025 from the same period last year, while for Sep 2025 it was 44.44%, marking a year-over-year increase of 11884.00%. This contributed to the annual value of -72.92% for FY2024, which is 2466.00% up from last year.
  • Theravance Biopharma's EBITDA Margin amounted to 18.29% in Q3 2025, which was down 91.26% from 209.30% recorded in Q2 2025.
  • In the past 5 years, Theravance Biopharma's EBITDA Margin ranged from a high of 7,361.30% in Q3 2022 and a low of -1,038.96% during Q1 2022.
  • For the 3-year period, Theravance Biopharma's EBITDA Margin averaged around -54.59%, with its median value being -74.85% (2024).
  • Per our database at Business Quant, Theravance Biopharma's EBITDA Margin soared by 762,886bps in 2022 and then plummeted by 741,794bps in 2023.
  • Quarterly analysis of 5 years shows Theravance Biopharma's EBITDA Margin stood at -375.80% in 2021, then soared by 25,680bps to -119.00% in 2022, then spiked by 8,347bps to -35.53% in 2023, then tumbled by 1,353bps to -49.06% in 2024, then skyrocketed by 9,315bps to 18.29% in 2025.
  • Its last three reported values are 18.29% in Q3 2025, 209.30% for Q2 2025, and -88.29% during Q1 2025.